Summary
Latest filing:
Anthony E. Maida III is DIRECTOR AND CMO - TRANS. MED., Director of Oncotelic Therapeutics, Inc. (OTLC). 1 SEC Form 4 filing on record, dated 14 July 2026.
Trading Pattern
InsiderAlpha's records for Anthony E. Maida III go back to 2026: 1 primary Form 4 filing, an average of 1.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Anthony E. Maida III files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Vuong Trieu - $37K of OTLC open-market activity in the last 12 months
- Amit B. Shah - $1K of OTLC open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Anthony E. Maida III?
Anthony E. Maida III is a corporate insider, tracked as DIRECTOR AND CMO - TRANS. MED., Director of Oncotelic Therapeutics, Inc. (OTLC). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Anthony E. Maida III submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Anthony E. Maida III's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Anthony E. Maida III and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial